Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke
Recruiting now · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Ischemic Stroke, Acute, Cerebrovascular Disorders, Brain Disorder, Central Nervous System Diseases
In brief
Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b/3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.
Key facts
- Study ID
- NCT05892510
- Run by
- University of Melbourne
- People needed
- 462
- Starts
- 2024-06-01
- Expected to finish
- 2027-11-30
- Last updated by the study team
- 2026-05-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT/MR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:
- For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT
- For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume <100ml.
- Qualifying CT/MR within 4hrs of randomisation (repeat CT for transferred participants required if >4hr)
- Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)
- Local legal requirements for consent have been satisfied.
You may not qualify if…
- Intracranial hemorrhage identified by CT or MRI
- ASPECTS 0-2 on NCCT
- CTP or MRI perfusion ischemic core volume >100ml if presenting within 6-24 hours from symptoms onset
- Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis/occlusion.
- More than six retrieval attempts in the same vessel
- Alteplase being infused within 30 minutes (\~5x half-life) of anticipated trial drug administration
- Contraindication to imaging with contrast agents
- Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated
- Pregnant women.
- Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.
- Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.
- Other standard contraindications to thrombolysis apart from time window.
- Known terminal illness such that the participants would not be expected to survive a year.
- Planned withdrawal of care or comfort care measures.
Where it is running
- Gold Coast Univeristy Hospital — Gold Coast, Queensland, Australia (enrolling)
- Royal Adelaide Hospital — Adelaide, Australia (enrolling)
- Alfred Hospital — Melbourne, Australia (enrolling)
- Austin Hospital — Melbourne, Australia (enrolling)
- Monash Medical Centre — Melbourne, Australia (enrolling)
- Royal Melbourne Hospital — Melbourne, Australia (enrolling)
- Fiona Stanley Hospital — Perth, Australia (enrolling)
- Sir Charles Gairdner Hospital — Perth, Australia (enrolling)
- Liverpool Hospital — Sydney, Australia (enrolling)
- Royal North Shore Hospital — Sydney, Australia (enrolling)
- Townsville University Hospital — Townsville, Australia (enrolling)
- Christchurch Hospital — Christchurch, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.